"Clinical studies have shown that both GLP-1 [glucagon-like peptide-1] receptor agonists and SGLT2 [sodium-glucose cotransporter 2] inhibitors yield additional clinical benefits compared with older treatments in reducing body weight and progression of cardiovascular disease and chronic kidney disease," write Shichao Tang, PhD, from the US Centers for Disease Control and Prevention , Atlanta, Georgia, and colleagues.
Excluding those who likely had type 1 diabetes and those with incomplete data left 1330 survey participants, including 1133 who fit criteria for the treatment of type 2 diabetes with an agent from one of the two studied classes, asby a panel representing the American Diabetes Association and the European Association for the Study of Diabetes.